Oral bile acids in cystic fibrosis-associated liver disease.
作者信息
Colombo C, Crosignani A, Apostolo M G, Marzano M T, Bettinardi N, Giunta A
机构信息
Department of Paediatrics, University of Milan, Italy.
出版信息
J R Soc Med. 1994;87 Suppl 21(Suppl 21):20-4.
Abstract
摘要
相似文献
1
Oral bile acids in cystic fibrosis-associated liver disease.
J R Soc Med. 1994;87 Suppl 21(Suppl 21):20-4.
2
Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review.熊去氧胆酸在囊性纤维化相关肝病中的应用：一项系统评价
J R Soc Med. 1997;90 Suppl 31(Suppl 31):6-12. doi: 10.1177/014107689709031S03.
3
Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.熊去氧胆酸治疗囊性纤维化相关肝病：一项剂量反应研究。
Hepatology. 1992 Oct;16(4):924-30. doi: 10.1002/hep.1840160412.
4
Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.对囊性纤维化及相关肝病患者在服用熊去氧胆酸（UDCA）前后胆汁胆汁酸成分的综合研究。
Hepatology. 1990 Aug;12(2):322-34. doi: 10.1002/hep.1840120221.
5
Ursodeoxycholic acid in the treatment of chronic liver disease.
Am J Gastroenterol. 1994 Sep;89(9):1447-52.
6
Ursodeoxycholic acid for cystic fibrosis-related liver disease.熊去氧胆酸用于治疗囊性纤维化相关肝病。
Cochrane Database Syst Rev. 2014 Dec 15(12):CD000222. doi: 10.1002/14651858.CD000222.pub3.
7
Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.血清胆汁酸及熊去氧胆酸治疗囊性纤维化相关肝病
Eur J Gastroenterol Hepatol. 1996 May;8(5):477-83.
8
Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.熊去氧胆酸治疗囊性纤维化相关肝病的效果
J Pediatr. 1990 Sep;117(3):482-9. doi: 10.1016/s0022-3476(05)81103-5.
9
Cystic fibrosis. Is treatment with ursodeoxycholic acid of value?
Scand J Gastroenterol Suppl. 1994;204:65-7. doi: 10.3109/00365529409103628.
10
Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease.熊去氧胆酸治疗有发生肝病风险的囊性纤维化患者。
Dig Liver Dis. 2010 Jun;42(6):428-31. doi: 10.1016/j.dld.2009.07.022. Epub 2010 Jan 19.
引用本文的文献
1
Clinical pharmacokinetics of therapeutic bile acids.治疗性胆汁酸的临床药代动力学
Clin Pharmacokinet. 1996 May;30(5):333-58. doi: 10.2165/00003088-199630050-00002.
本文引用的文献
1
The changing epidemiology of cystic fibrosis.囊性纤维化不断变化的流行病学
J Pediatr. 1993 Jan;122(1):1-9. doi: 10.1016/s0022-3476(05)83478-x.
2
Regulation of membrane chloride currents in rat bile duct epithelial cells.大鼠胆管上皮细胞膜氯化物电流的调节
J Clin Invest. 1993 Jan;91(1):319-28. doi: 10.1172/JCI116188.
3
Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts.囊性纤维化中的肝胆疾病：当前问题与概念综述
J Pediatr Gastroenterol Nutr. 1982;1(4):469-78. doi: 10.1097/00005176-198212000-00005.
4
Effect of taurine supplements on fat absorption in cystic fibrosis.
Pediatr Res. 1985 Jun;19(6):578-82. doi: 10.1203/00006450-198506000-00015.
5
Cystic fibrosis: ultrasonographic findings in the pancreas and hepatobiliary system correlated with clinical data and pathology.
Clin Radiol. 1985 Mar;36(2):199-203. doi: 10.1016/s0009-9260(85)80120-3.
6
Epidemiology of ulcerative colitis in western Norway.
Scand J Gastroenterol. 1988 Jun;23(5):517-22. doi: 10.3109/00365528809093904.
7
Excessive fecal taurine loss predisposes to taurine deficiency in cystic fibrosis.粪便中牛磺酸过度流失易导致囊性纤维化患者出现牛磺酸缺乏。
J Pediatr Gastroenterol Nutr. 1988 Mar-Apr;7(2):214-9. doi: 10.1097/00005176-198803000-00010.
8
Liver disease and common-bile-duct stenosis in cystic fibrosis.囊性纤维化中的肝脏疾病和胆总管狭窄
N Engl J Med. 1988 Feb 11;318(6):340-6. doi: 10.1056/NEJM198802113180602.
9
Deterioration of primary biliary cirrhosis during treatment with ursodeoxycholic acid.熊去氧胆酸治疗期间原发性胆汁性肝硬化的病情恶化。
Lancet. 1988 May 21;1(8595):1163. doi: 10.1016/s0140-6736(88)91974-5.
10
Ursodeoxycholic acid in biliary atresia.熊去氧胆酸治疗胆道闭锁
Lancet. 1988 Mar 5;1(8584):528. doi: 10.1016/s0140-6736(88)91313-x.
Zotero 插件